ABBVIE (ABBV) DIvidends Date & History

Key Takeaways

• AbbVie pays a quarterly dividend of $1.73 per share, for an annualized total of $6.92.
• The current dividend yield stands at approximately 2.67%.
• The company has raised its dividend annually since its 2013 spin-off and belongs to the S&P Dividend Aristocrats Index.
• Payout ratio is around 63%, indicating strong earnings coverage for the dividend.
• Free cash flow supports ongoing dividend payments and modest growth.
• AbbVie offers a balanced profile for income and dividend growth investors.

Dividend Overview

AbbVie maintains a quarterly dividend payment schedule with the most recent ex-dividend date on July 15, 2026, and the corresponding payment scheduled for August 14, 2026. The annualized dividend totals $6.92 per share, resulting in a yield near 2.67%. The company follows a consistent dividend policy focused on steady increases supported by its pharmaceutical operations. AbbVie is viewed as a dividend growth stock rather than a high-yield name, offering moderate income combined with a track record of annual raises. This profile appeals to investors seeking reliable payouts alongside potential for long-term compounding.

Dividend History and Growth

Since its formation through the 2013 spin-off from Abbott Laboratories, AbbVie has increased its dividend every year. The quarterly payout has risen from $0.40 at inception to the current $1.73 level, representing substantial cumulative growth. The company has delivered an annualized dividend growth rate of roughly 5% to 6% in recent years while maintaining its position in the S&P Dividend Aristocrats Index. This consistency reflects a long-term strategy of returning capital to shareholders through progressive dividend increases backed by stable cash generation from key products.

Dividend Sustainability and Payout Ratio

AbbVie’s payout ratio of approximately 63% demonstrates solid earnings coverage for its dividend. The company generates robust free cash flow that comfortably exceeds dividend requirements, providing a buffer for continued payments even during periods of revenue fluctuation typical in the pharmaceutical sector. Debt levels remain manageable relative to cash flow, supporting overall financial stability. These factors point to a sustainable dividend that appears well-positioned for ongoing modest growth without straining the balance sheet.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, AbbVie’s dividend yield of about 2.67% exceeds the typical range offered by many large-cap peers, which often fall between 1.5% and 2.5%. While some competitors emphasize higher growth or lower yields, AbbVie combines a competitive payout with a proven history of annual increases. This positions the stock as relatively attractive on an income basis compared with peers that may prioritize reinvestment over distributions.

AI Screener

AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Is This Stock Attractive for Dividend Investors?

AbbVie may suit income-oriented investors seeking a moderate yield with a history of annual dividend growth. Dividend growth investors could find the consistent increases and Aristocrat status appealing for long-term compounding. Conservative investors might value the sustainable payout ratio and cash flow coverage that support reliability across market cycles. The stock’s profile aligns with those prioritizing stability over maximum yield, though results depend on individual portfolio needs and market conditions. No investment recommendation is implied.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations